ProteoNic and ORYZON awarded European grant for joint development of therapeutic antibodies against prostate cancer
ProteoNic and ORYZON genomics have joined forces to develop new antibodies against prostate cancer and generate cost-effective production-ready cell lines. ProteoNic will use its expression expertise and UNic™ toolbox production yield enhancer to optimize the potential of ORYZON’s proprietary targets without compromising antibody quality. By awarding the joint venture a EuroTrans-Bio grant, the EU recognizes the unique combination of skills that will serve an unmet medical need for new prostate cancer diagnostics and treatment.
The new venture is focusing on identifying antibodies against prostate cancer-specific markers while validating these markers. ORYZON and ProteoNic are also developing faster and more cost-effective ways of identifying, characterizing and producing therapeutic monoclonal antibodies to combat the disease. The companies expect to select and produce antibodies for preclinical proof-of-concept studies within the next two years.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Category:Pharmaceutical_companies_of_the_United_States
Recombinant and Prophylactic Treatments Boost Global Haemophilia Therapeutics Market - Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan
US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's Nepicastat in Cocaine Dependence
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
Multi-drug resistant infections rising in children

Mother’s intestinal microbes strengthen newborn babies
Novartis makes offer for NeuTec Pharma - Acquisition adds two highly promising biotech drugs to portfolio
Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS
Researchers explore epigenetic influences of chronic pain
Focussed ultrasound used to improve effects of cancer drugs
